Medindia

X

Genoptix, Inc. to Announce Third Quarter 2009 Financial Results

Thursday, October 22, 2009 General News J E 4
Advertisement

CARLSBAD, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a provider of personalized diagnostic services, announced today that it expects to report its financial results for the third quarter of 2009 after closing of the NASDAQ Global Market on Thursday, November 5, 2009.

A conference call hosted by President and CEO, Dr. Tina S. Nova, and other members of senior management will take place on the same day at 2:00pm PST (5:00pm EST) and will be webcast live on the Genoptix website.  

To access the live conference call via phone, dial 1-866-318-8620 in the U.S. or Canada and 1-617-399-5139 for international callers.  Please specify to the operator that you would like to join the "Genoptix Third Quarter 2009 Earnings Conference Call." The participant code for the call is 65066785. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, November 12, 2009.  Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 62495576.

The conference call will be webcast live on the Internet and is accessible through the "Investors" section of the Genoptix website at www.genoptix.com, or by accessing the external website, www.fulldisclosure.com.  To participate in the webcast, please connect to the Genoptix website several minutes prior to the start time to register, download and install any necessary software that may be required.  An online replay is planned to follow shortly after and will be available until Thursday, December 3, 2009.  

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists.  Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma.  Genoptix is a member the S&P SmallCap 600 Index and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.

Any statements in this press release or that may be made on the Genoptix conference call about expectations, beliefs, plans, objectives, assumptions or future events, or future performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties that Genoptix faces, please refer to the "Risk Factors" section in the Company's most recent Annual Report on Form  10-K, as well as other subsequent filings with the Securities and Exchange Commission.  Genoptix assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

SOURCE Genoptix, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
First Intra-Arrest Cooling Study Chosen for AHA Sc...
S
Zimmer Holdings, Inc. Reports Third Quarter 2009 F...